Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

The following is a summary of “Dose-response relationship between Life's Essential 8 score and COPD risk: the NHANES cohort ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

HealthDay News — In clinical practice guidelines jointly issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Jan. 21 in the Annals of Internal ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...

In a recent clinical guideline, recommendations are presented for the diagnosis and management of eosinophilic esophagitis.